Some patients may experience minimal discomfort, while others may find the side effects more challenging to manage
Several active research areas include: Metabolic dysfunction-associated steatotic liver disease (MASLD) : Multiple trials are evaluating semaglutide's effects on liver fat content and biomarkers, with preliminary data suggesting potential benefits in reducing hepatic steatosis and improving liver enzyme profiles Chronic kidney disease : Studies examining renal outcomes in patients with type 2 diabetes and established kidney disease, building on secondary analyses from SUSTAIN 6 showing reduced progression of diabetic nephropathy Obstructive sleep apnea : Ongoing trials investigating whether weight loss achieved with semaglutide improves sleep apnea severity and related cardiovascular outcomes Addiction and substance use disorders : Early-phase research exploring GLP-1 receptor agonists' potential effects on reward pathways and addictive behaviors, though this remains highly preliminary Alzheimer's disease and cognitive function : Preclinical evidence suggesting neuroprotective properties has prompted clinical trials examining cognitive outcomes in at-risk populations Researchers are also investigating combination therapies , such as cagrilintide plus semaglutide (CagriSema), which is currently under development
Standard GI research endpoints include: macroscopic damage scoring (CDAI-equivalent scales in IBD models), histological assessment (H&E staining, villus/crypt morphometry), tight junction protein expression (Western blot, immunofluorescence), permeability assays (FITC-dextran, Ussing chambers), and inflammatory cytokine panels
A wide spectrum of atypical nuclear changes may be seen in such lesions, but these changes generally are reactive, degenerative, or senescent phenomena rather than true anaplastic atypia characteristic of malignant transformation
In general, GLP-1 is thought to have two effects, one exerted via the central nervous system and the other exerted via local receptors in the periphery
In clinical trials, nausea rates reached 44 percent at the highest Wegovy dose
